Dr Reddy’s Labs Q3 results reported only an increase of 2% on a year-on-year basis to ₹1,413 crores in the Q3 of the financial year 2024-25. The results were announced on January 23, 2025 and Dr Reddy’s Labs share price closed at ₹1,289.40. On the next day, Dr Reddy’s Labs share price opened with a fall to ₹1,229.95. Let’s unfold all the Dr Reddy’s Laboratories Q3 earnings findings including segment and geography-wise performance.
Dr Reddy’s Laboratories Q3 Results: Key Highlights
- The leading pharmaceutical company’s consolidated revenue rises by 16% YoY to ₹8,359 crores in the Q3 of FY25.
- EBITDA rose by 9% to ₹2,298 crores while R&D expenses rose by 20% to ₹666 crores in the third quarter.
- Gross margin was at 58.7%, which was higher than 58.5% in the third quarter of FY24 as per Dr Reddy’s Labs Q3 results.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
| Consolidated Numbers | Q3 FY25 | Q3 FY24 | YoY Change |
|---|---|---|---|
| Net Profit | 1,413 | 1,379 | 2% |
| Revenue | 8,359 | 7,215 | 16% |
| EBITDA | 2,298 | 2,111 | 9% |
| R&D Expenses | 666 | 557 | 20% |
*(in ₹ crores)
Dr Reddy’s Labs Q3 Results: Segment-wise Revenue
- Pharmaceutical Services and Active Ingredients: This segment witnessed a 2% YoY drop in consolidated revenue. On a standalone basis, this segment had a 5% YoY increase due to an increase in volume, new product launches, and favorable forex.
- Global Generics: This segment had 17% YoY growth in consolidated revenue mainly driven by revenues generated from the acquired NRT (Nicotine Replacement Therapy) portfolio, higher volumes, and new product launches.
| Segment Revenue | Q3 FY25 | Q3 FY24 | YoY Change |
|---|---|---|---|
| Pharmaceutical Services and Active Ingredients | 1,022 | 1,039 | -2% |
| Global Generics | 7,375 | 6,310 | 17% |
*(in ₹ crores)
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Dr Reddy’s Labs Q3 Results: Geography-wise Revenue
- North America: The volume growth is driven by new product launches and favorable forex.
- Europe: This segment’s high growth was driven by revenues generated from the NRT portfolio and new product launches.
- India: The growth was led by the revenues generated from the in-licensed vaccine portfolio, new product launches as well as price increases.
| Geography Revenue | Q3 FY25 | Q3 FY24 | YoY Change |
|---|---|---|---|
| North America | 3,383 | 3,349 | 1% |
| Europe | 1,210 | 497 | 143% |
| India | 1,346 | 1,180 | 14% |
| Emerging Markets | 1,436 | 1,283 | 12% |
*(in ₹ crores)
Dr Reddy’s Labs Q3 Results: Management Commentary
G V Prasad, Co-Chairman & MD of Dr Reddy’s Laboratories said, “We delivered double digit growth aided by our newly acquired NRT business, new launches and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability and innovation.”
Highlighting Dr Reddy’s Labs share price performance, it has generated a negative return of more than 5% in the last 1 week (as on January 24, 2025). Keep exploring stocks and open demat account with SMC Global Securities. Stay tuned for the upcoming Nifty 50 companies quarterly results.
References:
SMC Global Securities Research Team
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
